Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma
Ramucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2. In two randomised clinical trials Ramucirumab either alone or in combination with paclitaxel has been found to be safe and effective for patients with previously treated advanced gastric cancer. One of the...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2018-07-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2548 |
| _version_ | 1797841611230543872 |
|---|---|
| author | T. A. Titova N. S. Besova V. A. Gorbunova Yu. P. Kuvshinov A. A. Filatov A. F. Ketsba A. A. Fedenko |
| author_facet | T. A. Titova N. S. Besova V. A. Gorbunova Yu. P. Kuvshinov A. A. Filatov A. F. Ketsba A. A. Fedenko |
| author_sort | T. A. Titova |
| collection | DOAJ |
| description | Ramucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2. In two randomised clinical trials Ramucirumab either alone or in combination with paclitaxel has been found to be safe and effective for patients with previously treated advanced gastric cancer. One of the serious adverse events associated with ramucirumab is bleeding.We report the case of a 56-year-old man with advanced gastric cancer located at the gastroesophageal junction with liver, pulmonary and multiple lymph node metastases, plevritis was treated with a paclitaxel plus Ramucirumab regimen. We demonstrate a case of a cardioesophageal junction bleeding due to the high efficiency of treatment. He was successfully treated with by applying only hemostatical therapy, but after stop the bleeding chemotherapy was not reintroduced. The partial response was maintained for approximately 10 months. The patient died on 28 November 2017.Chemotherapy with best supportive care for metastatic gastric cancer shown the improvement the performance status, help keep the cancer under control and help relieve symptoms during the time. |
| first_indexed | 2024-04-09T16:34:05Z |
| format | Article |
| id | doaj.art-1d214f4ef1ef4d17806329983efe7e4b |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:34:05Z |
| publishDate | 2018-07-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-1d214f4ef1ef4d17806329983efe7e4b2023-04-23T06:56:59ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-07-0101015015310.21518/2079-701X-2018-10-150-1532509Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinomaT. A. Titova0N. S. Besova1V. A. Gorbunova2Yu. P. Kuvshinov3A. A. Filatov4A. F. Ketsba5A. A. Fedenko6N.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of RussiaN.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of RussiaN.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of RussiaN.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of RussiaN.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of RussiaN.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of RussiaN.N.Blokhin Russian Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of RussiaRamucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2. In two randomised clinical trials Ramucirumab either alone or in combination with paclitaxel has been found to be safe and effective for patients with previously treated advanced gastric cancer. One of the serious adverse events associated with ramucirumab is bleeding.We report the case of a 56-year-old man with advanced gastric cancer located at the gastroesophageal junction with liver, pulmonary and multiple lymph node metastases, plevritis was treated with a paclitaxel plus Ramucirumab regimen. We demonstrate a case of a cardioesophageal junction bleeding due to the high efficiency of treatment. He was successfully treated with by applying only hemostatical therapy, but after stop the bleeding chemotherapy was not reintroduced. The partial response was maintained for approximately 10 months. The patient died on 28 November 2017.Chemotherapy with best supportive care for metastatic gastric cancer shown the improvement the performance status, help keep the cancer under control and help relieve symptoms during the time.https://www.med-sovet.pro/jour/article/view/2548advanced gastric cancergastroesophageal cancersecond-line therapyramucirumabpaclitaxelbleeding |
| spellingShingle | T. A. Titova N. S. Besova V. A. Gorbunova Yu. P. Kuvshinov A. A. Filatov A. F. Ketsba A. A. Fedenko Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma Медицинский совет advanced gastric cancer gastroesophageal cancer second-line therapy ramucirumab paclitaxel bleeding |
| title | Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma |
| title_full | Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma |
| title_fullStr | Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma |
| title_full_unstemmed | Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma |
| title_short | Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma |
| title_sort | case report of the rapid achievement of sustained and long term remission resulting from the use of ramucirumab plus paclitaxel in the second line treatment of a patient with disseminated gastric adenocarcinoma |
| topic | advanced gastric cancer gastroesophageal cancer second-line therapy ramucirumab paclitaxel bleeding |
| url | https://www.med-sovet.pro/jour/article/view/2548 |
| work_keys_str_mv | AT tatitova casereportoftherapidachievementofsustainedandlongtermremissionresultingfromtheuseoframucirumabpluspaclitaxelinthesecondlinetreatmentofapatientwithdisseminatedgastricadenocarcinoma AT nsbesova casereportoftherapidachievementofsustainedandlongtermremissionresultingfromtheuseoframucirumabpluspaclitaxelinthesecondlinetreatmentofapatientwithdisseminatedgastricadenocarcinoma AT vagorbunova casereportoftherapidachievementofsustainedandlongtermremissionresultingfromtheuseoframucirumabpluspaclitaxelinthesecondlinetreatmentofapatientwithdisseminatedgastricadenocarcinoma AT yupkuvshinov casereportoftherapidachievementofsustainedandlongtermremissionresultingfromtheuseoframucirumabpluspaclitaxelinthesecondlinetreatmentofapatientwithdisseminatedgastricadenocarcinoma AT aafilatov casereportoftherapidachievementofsustainedandlongtermremissionresultingfromtheuseoframucirumabpluspaclitaxelinthesecondlinetreatmentofapatientwithdisseminatedgastricadenocarcinoma AT afketsba casereportoftherapidachievementofsustainedandlongtermremissionresultingfromtheuseoframucirumabpluspaclitaxelinthesecondlinetreatmentofapatientwithdisseminatedgastricadenocarcinoma AT aafedenko casereportoftherapidachievementofsustainedandlongtermremissionresultingfromtheuseoframucirumabpluspaclitaxelinthesecondlinetreatmentofapatientwithdisseminatedgastricadenocarcinoma |